Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer

Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer

Abstract Background Eribulin mesylate (ERI; Halaven®) is a microtubule inhibitor approved in the United States for metastatic breast cancer patients with at least two prior chemotherapy regimens for metastatic breast cancer, and in the European Union in locally advanced breast cancer or metastatic b...

Full description

Bibliographic Details
Main Authors: Qi Zhao, Rachel Hughes, Binod Neupane, Kristin Mickle, Yun Su, Isabelle Chabot, Marissa Betts, Ananth Kadambi
Format: Article
Language:English
Published: BMC 2021-06-01
Series:BMC Cancer
Subjects:
Breast cancer
Metastatic
Locally advanced
Network meta-analysis
Triple negative breast cancer, overall survival
Online Access:https://doi.org/10.1186/s12885-021-08446-8

Internet

https://doi.org/10.1186/s12885-021-08446-8

Similar Items